Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Sarcopenia Is A Novel Poor Prognostic Factor In Male Patients With Pathological Stage I Non-small Cell Lung Cancer

T. Tsukioka, N. Nishiyama, N. Izumi, S. Mizuguchi, H. Komatsu, S. Okada, M. Toda, Kantaro Hara, R. Ito, T. Shibata
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Objectives Sarcopenia is the progressive loss of muscle mass and strength, and has a risk of adverse outcomes such as disability, poor quality of life and death. As prognosis depends not only on disease aggressiveness, but also on a patient's physical condition, sarcopenia can predict survival in patients with various cancer types. However, its effects on postoperative prognosis in patients with localized non-small cell lung cancers (NSCLC) have never been reported. Methods We retrospectively investigated 215 male patients with pathological Stage I NSCLC. L3 muscle index is defined as the cross-section area of muscle at the third lumbar vertebra level, normalized for height, and is a clinical measurement of sarcopenia. We then investigated the effect of preoperative sarcopenia on their postoperative prognosis. Results Our 215 subjects included 30 patients with sarcopenia. Sarcopenia was significantly associated with body mass index, nutritional condition, serum CYFRA 21-1 level and pathological stage, but not with preoperative respiratory function or performance status. Frequency of postoperative complications, length of postoperative hospital stay, thoracic drainage period or causes of death were not correlated with the presence of sarcopenia. The sarcopenia group had a significantly shorter median overall survival (32 months) than the no-sarcopenia group. Conclusion Sarcopenia might not affect short-term outcomes in patients with early-stage lung cancer. Sarcopenia was a predictor of poor prognosis in male patients with Stage I NSCLC. As sarcopenic patients with NSCLC patients are at risk for significantly worse outcomes, their treatments require careful planning, even for those with Stage I disease.
This paper references
Body composition and outcome in patients undergoing resection of colorectal liver metastases
M. G. van Vledder (2012)
Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer
M. Kimura (2014)
Carcinoembryonic antigen ( CEA ) as tumor marker in
T Kawai (2012)
Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image.
Wei Shen (2004)
: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system
SE Jones (2012)
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
Trevor J Bayliss (2011)
Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
C.M. Op den Kamp (2012)
Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia.
R. Fielding (2011)
Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer
E. Kim (2015)
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.
C. Nishida (2004)
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.
H. Kato (2004)
Cancer cachexia and fat-muscle physiology.
K. Fearon (2011)
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer.
M. Grunnet (2012)
Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation
S. Jones (2015)
Prognostic value of body mass index and change in body weight in postoperative outcomes of lung cancer surgery.
T. Nakagawa (2016)
Sarcopenia as a Prognostic Biomarker of Advanced Urothelial Carcinoma
H. Fukushima (2015)
Skeletal muscle area correlates with body surface area in healthy adults
T. Yoshizumi (2014)
Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options - A Mini-Review
S. Ali (2014)
Definition and classification of cancer cachexia: an international consensus.
K. Fearon (2011)
Clinicopathologic factors influencing postoperative prognosis in patients with small-sized adenocarcinoma of the lung.
M. Inoue (2008)
Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.
C. Prado (2008)
Study of standard level, cut off level, diagnostic specificity and sensitivity for a new tumor marker CYFRA in lung cancer measured by EIA
T Kawai (1993)
Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy
H. Jung (2014)
Sarcopenia as a Prognostic Factor among Patients with Stage III Melanoma
M. Sabel (2011)
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies
Who Expert Consultation (2004)
Effect of Postoperative Adjuvant Chemotherapy with Tegafur-Uracil on Survival in Patients with Stage IA Non-small Cell Lung Cancer: An Exploratory Analysis from a Meta-Analysis of Six Randomized Controlled Trials
C. Hamada (2009)
Optimal frequency/time combination of whole‐body vibration training for improving muscle size and strength of people with age‐related muscle loss (sarcopenia): A randomized controlled trial
N. Wei (2017)

This paper is referenced by
Positive correlation between sarcopenia and elevation of neutrophil/lymphocyte ration in pathological stage IIIA (N2-positive) non-small cell lung cancer patients
T. Tsukioka (2018)
Impact of Sarcopenia on Outcomes of Autologous Head and Neck Free Tissue Reconstruction.
Mohamedkazim M Alwani (2020)
Sarcopenia is a predictor of outcomes after lobectomy.
J. A. Miller (2018)
Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma
Hiroki Ishihara (2018)
Smoking, alcohol, and nutritional status in relation to one-year mortality in Danish stage I lung cancer patients.
Niels Lyhne Christensen (2018)
Low Thoracic Skeletal Muscle Area Predicts Morbidity after Pneumonectomy for Lung Cancer.
M. Madariaga (2019)
Sarcopenia predicts poor postoperative outcome in elderly patients with lung cancer
Y. Kawaguchi (2019)
Does sarcopenia have any impact on survival of patients with surgically treated non-small-cell lung cancer?
Han-Yu Deng (2019)
Loss of Muscle Mass Is a Novel Predictor of Postoperative Early Recurrence in N2-Positive Non-Small-Cell Lung Cancer
T. Tsukioka (2018)
Sarcopenia as Prognostic Factor in Lung Cancer Patients: A Systematic Review and Meta-analysis
J. Buentzel (2019)
Neutrophil-lymphocyte ratio predicts recurrence in patients with resected stage 1 non-small cell lung cancer
S. Mizuguchi (2018)
Impact of Sarcopenia on Surgical Outcomes in Non-small Cell Lung Cancer
Shuichi Shinohara (2020)
Expression of Cripto‐1 predicts poor prognosis in stage I non‐small cell lung cancer
Chunhua Xu (2020)
Sarcopenia and Myosteatosis at Presentation Adversely Affect Survival After Esophagectomy for Esophageal Cancer
M. Srpčič (2020)
Correction to: Positive correlation between sarcopenia and elevation of neutrophil/lymphocyte ratio in pathological stage IIIA (N2-positive) non-small cell lung cancer patients
T. Tsukioka (2019)
Sarcopenia Is Not a Prognostic Factor of Outcome in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy or Radiotherapy
H. Matsuoka (2019)
Thoracic skeletal muscle quantification: low muscle mass is related with worse prognosis in idiopathic pulmonary fibrosis patients
S. W. Moon (2019)
A Morphomic Index is an Independent Predictor of Survival after Lung Cancer Resection.
M. Ferguson (2019)
Prognostic significance of sarcopenia in patients undergoing esophagectomy for superficial esophageal squamous cell carcinoma.
J. Oguma (2019)
Prognostic Value of Sarcopenia in Lung Cancer: A Systematic Review and Meta-analysis.
Ming Yang (2019)
Computed Tomography-Assessed Skeletal Muscle Mass as a Predictor of Outcomes in Lung Cancer Surgery.
J. Nishimura (2019)
Risk factors and cancer recurrence associated with postoperative complications after thoracoscopic lobectomy for clinical stage I non‐small cell lung cancer
Takeo Nakada (2019)
Does Assessment of Frailty and Sarcopenia in Lung Resection Candidates Affect Patient Selection
M. Huisingh-Scheetz (2020)
Nutritional status and muscle dysfunction in chronic respiratory diseases: stable phase versus acute exacerbations.
J. Gea (2018)
Decrease in skeletal muscle index one year after radical cystectomy as a prognostic indicator in patients with urothelial bladder cancer
Yun-Sok Ha (2019)
Preoperative low skeletal muscle mass as a risk factor for pharyngocutaneous fistula and decreased overall survival in patients undergoing total laryngectomy
S. I. Bril (2019)
Sarcopenia is an independent unfavorable prognostic factor of non-small cell lung cancer after surgical resection: A comprehensive systematic review and meta-analysis.
Han-Yu Deng (2019)
Semantic Scholar Logo Some data provided by SemanticScholar